Phatisa, via Phatisa Food Fund 2, has agreed to sell its interest in Deltamune (Pty) Ltd, a leading South African vaccine manufacturer, to Vaxxinova International B.V., a global animal health company within the EW Group. This transaction enhances Vaxxinova’s presence in Africa and aligns with Phatisa’s strategy of creating impactful change through operational excellence. Financial specifics of the deal were not disclosed.
Founded in 1995, Deltamune specializes in developing and manufacturing vaccines primarily for production animals, especially poultry, and also for ruminants like cattle and sheep. The company produces around 15 million vaccine doses annually, serving 12 countries in the SADC and COMESA regions with products that include tailored autogenous vaccines and commercial vaccines against prevalent diseases such as Avian Influenza and Newcastle Disease.
In 2022, Phatisa, alongside management, acquired 100% of Deltamune from HL Hall & Sons, facilitating the company’s expansion across various markets. Under Phatisa’s guidance, Deltamune successfully entered three new markets, expanded its product range, and improved distribution capabilities.
Imane El Alaoui, Partner at Phatisa, stated, “Our partnership with Deltamune highlights our commitment to fostering innovation that delivers regional and global value. This exit exemplifies the potential of local production to enhance food security and pandemic resilience in Africa.”
Dr. Stefan Swanepoel, Managing Director of Deltamune, noted, “Phatisa’s support has empowered us to broaden our reach and strengthen animal health in the region. With Vaxxinova, we will enhance our capacity to respond to animal health threats.”
Victor van Solinge, CEO of Vaxxinova, expressed excitement about the acquisition, highlighting the cultural and operational alignment that will benefit stakeholders across South Africa and beyond.
This acquisition addresses growing global priorities related to food security and disease management. It is expected to enhance Africa’s ability to respond to health challenges by combining Deltamune’s established customer base with Vaxxinova’s research capabilities.
DLA Piper Advisory Services (Pty) Ltd served as legal advisor to Phatisa and Deltamune, while RSM South Africa provided legal advice and due diligence for Vaxxinova.r Vaxxinova. to Vaxxinova.
